Effects on sleep stages and microarchitecture of caffeine and its combination with zolpidem or trazodone in healthy volunteers

• Published in: Journal of psychopharmacology (Oxford) 2009-07, Vol.23 (5), p.487-494
• Main Authors: Paterson, LM, Nutt, DJ, Ivarsson, M, Hutson, PH, Wilson, SJ
• Format: Article
• Language: English
• Subjects: Adult; Antidepressants; Biological and medical sciences; Blindness; Caffeine; Caffeine - toxicity; Central Nervous System Stimulants - toxicity; Cross-Over Studies; Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes; Double-Blind Method; EEG; Electroencephalography; Eye; Humans; Hypnotics and Sedatives - pharmacology; Insomnia; Male; Medical sciences; Nervous system (semeiology, syndromes); Neurology; Neuropharmacology; Pharmacology. Drug treatments; Polysomnography; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopharmacology; Pyridines - pharmacology; REM sleep; Sleep; Sleep and wakefulness; Sleep disorders; Sleep Initiation and Maintenance Disorders - chemically induced; Sleep Initiation and Maintenance Disorders - drug therapy; Sleep Stages - drug effects; Trazodone - pharmacology; Young Adult; Zolpidem
• ISSN: 0269-8811; 1461-7285
• DOI: 10.1177/0269881109104852

Abstract Caffeine is the world’s most popular stimulant and is known to disrupt sleep. Administration of caffeine can therefore be used in healthy volunteers to mimic the effects of insomnia and thus to test the hypnotic effects of medication. This study assessed the effects of caffeine on sleep architecture and electroencephalography (EEG) spectrum alone and in combination with two different sleep-promoting medications. Home polysomnography was performed in 12 healthy male volunteers in a double-blind study whereby subjects received placebo, caffeine (150 mg), caffeine plus zolpidem (10 mg) and caffeine plus trazodone (100 mg) at bedtime in a randomised crossover design. In addition to delaying sleep onset, caffeine decreased total sleep time (TST), sleep efficiency (SE) and stage 2 sleep without significantly altering wake after sleep onset or the number of awakenings. Zolpidem attenuated the caffeine-induced decrease in SE and increased spindle density in the caffeine plus zolpidem combination compared with placebo. Trazodone attenuated the decrease in SE and TST, and it also increased stage 3 sleep, decreased the number of awakenings and decreased the spindle density. No significant changes in rapid eye movement (REM) sleep were observed, neither was any significant alteration in slow wave activity nor other EEG spectral measures, although the direction of change was similar to that previously reported for caffeine and appeared to ‘normalise’ after trazodone. These data suggest that caffeine mimics some, but not all of the sleep disruption seen in insomnia and that its disruptive effects are differentially attenuated by the actions of sleep-promoting compounds with distinct mechanisms of action.